0.92%
0.37%
-15.30%
-39.45%
-15.71%
-67.38%
-27.90%
AI Spotlight on STAA
Company Description
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery.
In addition, the company sells injector parts, and other related instruments and devices.It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.
STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Market Data
| Last Price | 24.19 |
| Change Percentage | 0.92% |
| Open | 23.56 |
| Previous Close | 23.97 |
| Market Cap ( Millions) | 1192 |
| Volume | 538251 |
| Year High | 52.68 |
| Year Low | 21.13 |
| M A 50 | 24.98 |
| M A 200 | 34.9 |
Financial Ratios
| FCF Yield | 3.69% |
| Dividend Yield | 0.00% |
| ROE | 5.39% |
| Debt / Equity | 9.34% |
| Net Debt / EBIDTA | -392.59% |
| Price To Book | 2.78 |
| Price Earnings Ratio | 54.65 |
| Price To FCF | 27.11 |
| Price To sales | 3.49 |
| EV / EBITDA | 33.81 |
News
- Jan -31 - STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
- Jan -13 - STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
- Oct -31 - STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript
- Oct -31 - CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results
- Oct -30 - Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
- Oct -07 - Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher
- Sep -27 - Fast Money traders share their favorite stocks of the week
- Sep -27 - Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know
- Sep -20 - 4 Stocks to Buy Amid Dental Supplies Industry Challenges
- Sep -16 - Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade
- Sep -05 - STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
- Aug -12 - Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention
- Aug -09 - STAAR Surgical Company (STAA) Q2 2024 Earnings Call Transcript
- Aug -08 - Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say
- Aug -07 - Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
- Jun -27 - Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
- Jun -07 - Top 4 Stocks With Notable Insider Buying
- May -13 - Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock
- May -08 - STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript
- May -08 - Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Implantable Collamer Lenses
Expected Growth : 12.0 %
What the company do ?
Implantable Collamer Lenses from STAAR Surgical Company are a type of refractive surgical implant designed to correct nearsightedness and farsightedness.
Why we expect these perspectives ?
STAAR Surgical's Implantable Collamer Lenses' 12.0% growth driven by increasing demand for refractive surgery, rising prevalence of myopia and presbyopia, expanding adoption in emerging markets, and innovative product enhancements. Additionally, growing awareness of visual freedom and convenience, coupled with a strong distribution network, contribute to the segment's rapid growth.
Segment n°2 -> Other Surgical Products
Expected Growth : 10.0 %
What the company do ?
Other Surgical Products from STAAR Surgical Company include implantable lenses, injectors, and other surgical instruments for ophthalmic procedures.
Why we expect these perspectives ?
STAAR Surgical's 10.0% growth in Other Surgical Products is driven by increasing adoption of minimally invasive surgeries, rising demand for ophthalmic procedures, and expansion into emerging markets. Additionally, the company's strategic partnerships and investments in R&D have enhanced its product portfolio, contributing to the segment's growth.
Segment n°3 -> Cataract Intraocular Lenses
Expected Growth : 11.0 %
What the company do ?
Cataract Intraocular Lenses from STAAR Surgical Company are artificial lenses implanted in the eye to replace natural lenses, restoring vision after cataract removal.
Why we expect these perspectives ?
STAAR Surgical's 11.0% growth in Cataract Intraocular Lenses is driven by increasing demand for premium lenses, expanding adoption in emerging markets, and a growing elderly population. Additionally, advancements in lens technology, such as toric and multifocal lenses, are driving sales. The company's strategic partnerships and expanded distribution channels also contribute to its growth.
Staar Surgical Company Products
| Product Range | What is it ? |
|---|---|
| Visian Implantable Collamer Lenses (ICLs) | A type of refractive implant designed to correct nearsightedness, farsightedness, and astigmatism. |
| EVO/EVO+ Visian Implantable Collamer Lenses (ICLs) | Advanced versions of ICLs with improved design and materials for better visual outcomes. |
| KS-Aquport | A micro-incisional device used in cataract surgery to create a precise and stable incision. |
| NanoFlex | A range of intraocular lenses (IOLs) designed for cataract surgery and refractive lens exchange. |
| TORIC IOLs | Intraocular lenses designed to correct astigmatism in cataract surgery. |
STAAR Surgical Company's Porter Forces
Threat Of Substitutes
STAAR Surgical Company's Visian ICL and EVO/EVO+ lenses are unique products with no direct substitutes, but patients may opt for alternative treatments such as LASIK or PRK, which could impact sales.
Bargaining Power Of Customers
STAAR Surgical Company's customers, primarily ophthalmologists and optometrists, have limited bargaining power due to the company's strong brand reputation and limited alternative suppliers.
Bargaining Power Of Suppliers
STAAR Surgical Company's suppliers, primarily manufacturers of raw materials, have limited bargaining power due to the company's large scale of operations and diversified supply chain.
Threat Of New Entrants
The ophthalmic industry has high barriers to entry, including significant R&D investments, regulatory approvals, and established distribution networks, making it difficult for new entrants to compete with STAAR Surgical Company.
Intensity Of Rivalry
The ophthalmic industry is highly competitive, with established players such as Alcon, Johnson & Johnson, and Bausch + Lomb, leading to intense rivalry and competition for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.50% |
| Debt Cost | 3.95% |
| Equity Weight | 91.50% |
| Equity Cost | 7.95% |
| WACC | 7.61% |
| Leverage | 9.28% |
STAAR Surgical Company : Quality Control
STAAR Surgical Company passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| NXGL | NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The … |
| INFU | InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) … |
| ATRI | Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products … |
| ANGO | AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use … |
| FEMY | Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Atrion
A-Score
1-Year Total Return ->
🥈
NEXGEL
A-Score
1-Year Total Return ->
🥉
STAAR Surgical
A-Score
1-Year Total Return ->
4
InfuSystem Holdings
A-Score
1-Year Total Return ->
5
AngioDynamics
A-Score
1-Year Total Return ->
6
